Vivesto AB (FRA:OMA) Moat Score: 4/10 (As of Jul. 03, 2026)


FRA:OMA Vivesto AB FRA:OMA
33 GF Score
Price €0.70
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Moat Score?

Vivesto AB FRA:OMA -1.68% 33 Moat Score is 4 as of Jul. 03, 2026. GuruFocus rates FRA:OMA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,032 Drug Manufacturers companies, Vivesto AB ranks better than 90.7% on this metric.

Vivesto AB has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Vivesto AB has Narrow Moat: Vivesto AB has a discernible but modest moat due to its focus on pharmaceutical development. It holds some valuable intellectual property and patents, but faces significant competition and lacks strong brand strength or network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vivesto AB might have Narrow Moat - Discernible but modest moat.

Vivesto AB  (FRA:OMA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vivesto AB Moat Score Related Terms

FRA:OMA vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivesto AB Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Moat Score falls into.


FRA:OMA
33GF Score
Vivesto AB FRA:OMA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Vivesto AB (FRA:OMA) has a Moat Score of 4 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vivesto AB ranks #96 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Vivesto AB's Moat Score too high?
Vivesto AB's current Moat Score is 4. Based on the distribution chart, Vivesto AB ranks #96 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivesto AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #96 out of 1032 companies for Moat Score. This places Vivesto AB in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Vivesto AB's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (FRA:OMA) has a current Moat Score of 4. The current Moat Score is 4. Vivesto AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vivesto AB (FRA:OMA), the current Moat Score is 4 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges VIVE:Sweden
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
33GF Score

Get the complete analysis for FRA:OMA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.70
Price